<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology and treatment of edema in adults with the nephrotic syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology and treatment of edema in adults with the nephrotic syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology and treatment of edema in adults with the nephrotic syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H613074949"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Edema is one of the major clinical manifestations of the nephrotic syndrome. The pathophysiology and treatment of edema in patients with the nephrotic syndrome will be reviewed here. More general issues such as the clinical manifestations, diagnosis, and general principles of the treatment of edema are discussed elsewhere as is the mechanism of hypoalbuminemia in the nephrotic syndrome.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6878.html" rel="external">"Clinical manifestations and evaluation of edema in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6884.html" rel="external">"General principles of the treatment of edema in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome", section on 'Hypoalbuminemia'</a>.)</p><p></p><p class="headingAnchor" id="H1"><span class="h1">UNDERFILLING VERSUS RENAL SODIUM RETENTION</span><span class="headingEndMark"> — </span>Two major factors, both of which lead to retention, have been thought to be responsible for the development of edema in patients with the nephrotic syndrome; it is likely that both contribute to a variable degree in individual patients [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary sodium retention that is directly induced by the kidney disease (<strong>overfill</strong> hypothesis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary sodium retention in which the low plasma oncotic pressure due to hypoalbuminemia promotes the movement of fluid from the vascular space into the interstitium, leading to underfilling of the vasculature and activation of the renin-angiotensin-aldosterone system (<strong>underfill</strong> hypothesis)</p><p></p><p>The clinical importance of distinguishing between these mechanisms is the ability to tolerate diuretic therapy. Diuretics are well tolerated in patients with renal sodium retention but, if underfilling is the primary mechanism, can lead to worsening hypovolemia as evidenced clinically by an elevation in serum creatinine. As will be described below, most patients tolerate diuretic therapy at least initially.</p><p class="headingAnchor" id="H2"><span class="h2">Starling's law</span><span class="headingEndMark"> — </span>The possible importance of arterial underfilling seems to be predicted from Starling's law, which states that the exchange of fluid between the plasma and the interstitium is determined by the hydraulic and oncotic pressures in each compartment:</p><p>Net filtration across the capillary wall</p><div class="formulaContainer"><div class="formula"><p>  =  LpS  x  (Delta, hydraulic pressure - Delta, oncotic pressure)</p></div></div><p>  =  LpS  x  [(P<sub>cap</sub> - P<sub>if</sub>) - s(Pi<sub>cap</sub> - Pi<sub>if</sub>)]</p><p>where Lp is the unit permeability (or porosity) of the capillary wall, S is the surface area available for fluid movement, P<sub>cap</sub> and P<sub>if</sub> are the capillary and interstitial fluid hydraulic pressures, Pi<sub>cap</sub> and Pi<sub>if</sub> are the capillary and interstitial fluid oncotic pressures, and s represents the reflection coefficient of proteins across the capillary wall (with values ranging from 0 if completely permeable to 1 if completely impermeable). The interstitial oncotic pressure is derived primarily from filtered plasma proteins and to a lesser degree proteoglycans in the interstitium.</p><p class="headingAnchor" id="H3"><span class="h3">Application to nephrotic syndrome</span><span class="headingEndMark"> — </span>At first glance, a reduction in plasma oncotic pressure induced by hypoalbuminemia would seem to favor the movement of fluid out of the vascular space into the interstitium and produce arterial underfilling. However, it is the <strong>transcapillary oncotic pressure gradient</strong> (plasma minus interstitium), not the plasma oncotic pressure alone, that acts to hold fluid within the vascular space. The normal interstitial oncotic pressure in humans is 10 to 15 mmHg (compared with approximately 26 mmHg in the plasma) due in part to accumulation of some of the small amount of albumin that is filtered across the capillary wall [<a href="#rid1">1,3</a>].</p><p>This distinction is important since the gradual fall in plasma oncotic pressure in the nephrotic syndrome is associated with a <strong>parallel decline</strong> in interstitial oncotic pressure (<a class="graphic graphic_figure graphicRef74352" href="/z/d/graphic/74352.html" rel="external">figure 1</a>) [<a href="#rid3">3,4</a>], which minimizes the change in the transcapillary oncotic pressure gradient and therefore minimizes fluid movement out of the vascular space and results in relative maintenance of the plasma volume. The following factors contribute to this protective response [<a href="#rid4">4,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoalbuminemia is associated with less albumin entry into the interstitium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The fluid that moves from the vascular space into the interstitium will lower the interstitial albumin concentration by dilution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is increased lymphatic flow, which, by bulk flow, will remove albumin as well.</p><p></p><p>As a result, there is usually little change in the transcapillary oncotic pressure gradient in patients with nephrotic syndrome and therefore little tendency to plasma volume depletion, unless the hypoalbuminemia is severe [<a href="#rid6">6</a>]. Similarly, the plasma volume is typically preserved after diuretic therapy for edema removal in patients with nephrotic syndrome as long as the patient is not overdiuresed [<a href="#rid7">7</a>].</p><p>The response is appreciably different after the rapid administration of large volumes of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> to patients with marked hypovolemia due to bleeding (eg, ruptured aortic aneurysm). In this setting, there is an <strong>acute</strong> dilutional reduction in the plasma albumin concentration without time for the interstitial albumin concentration to fall. As a result, the transcapillary oncotic pressure gradient is reduced and peripheral edema due to fluid movement out of the vascular space can occur before the restoration of normal intracardiac filling pressures.</p><p>It is important to appreciate that the absence of demonstrable plasma volume depletion when a nephrotic patient is edematous does not preclude an important role for underfilling. Initial underfilling can activate compensatory mechanisms (such as enhanced renin release) that then return the plasma volume toward normal at the price of extracellular volume expansion and edema. Such a sequence clearly occurs in heart failure [<a href="#rid8">8,9</a>]. Furthermore, patients with the nephrotic syndrome do not have the clear signs of volume expansion (and occasionally pulmonary edema) as can be seen with renal sodium retention due to acute glomerulonephritis [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Evidence supporting underfilling</span><span class="headingEndMark"> — </span>The following findings support an important role for hypoalbuminemia and underfilling in the pathogenesis of edema in some patients with the nephrotic syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>Some patients, primarily those with minimal change disease, have low rates of sodium excretion and elevated plasma renin activity, findings suggestive of volume depletion [<a href="#rid6">6,11,12</a>] (see <a class="local">'Volume regulatory hormones'</a> below). One study, for example, evaluated 30 children with early relapse of minimal change disease who were studied within a <strong>few days</strong> of the onset of relapse as indicated by persistent 3+ findings on the urine dipstick for protein; 21 had edema at the time of evaluation and were evaluated for symptoms or signs of hypovolemia which included tachycardia, peripheral vasoconstriction (eg, cold hands and feet), and oliguria [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Compared with the eight asymptomatic patients, the 13 patients with hypovolemic signs or symptoms had a higher plasma renin activity, higher plasma aldosterone and norepinephrine concentrations, and more sodium avidity as evidenced by a lower fractional excretion of sodium. The differences between the two groups could not be explained by differences in proteinuria or the degree of hypoproteinemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The normal serum total protein concentration is 6 to 8 g/dL (60 to 80 g/L), a little more than one-half of which (3.5 to 5.0 g/dL [35 to 50 g/L]) is normally comprised of albumin. The findings in the preceding study of children with early relapse of minimal change disease are consistent with dog studies in which severe reductions in the total protein concentration (mean 2.4 g/dL [24 g/L], normal 7.2 g/dL [72 g/L]) produced by plasmapheresis plus isotonic fluid replacement led to significant reductions in plasma volume and blood pressure and increases in plasma renin activity and plasma aldosterone concentration [<a href="#rid13">13,14</a>]. These hemodynamic changes were not seen with moderate reductions in total protein concentration to approximately 4.8 g/dL (48 g/L) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Starling's law predicts that, with increasingly <strong>severe</strong> hypoalbuminemia, washout of the interstitial oncotic pressure would eventually be complete and that further reductions in the plasma oncotic pressure would lower the transcapillary oncotic pressure gradient and tend to produce underfilling. Support for this hypothesis comes from a study of 22 children with nephrotic syndrome not due to minimal change disease [<a href="#rid15">15</a>]. Sixteen children had stable edema <strong>without</strong> marked sodium retention or changes in volume regulatory hormones; these patients had a mean plasma albumin concentration of 2.1 g/dL (21 g/L). In contrast, six had clinical (tachycardia, vasoconstriction, pallor, oliguria) and hormonal evidence of hypovolemia; these patients, four of whom had congenital nephrotic syndrome of the Finnish type, had a mean plasma albumin concentration of 0.8 g/dL (8 g/L). (See  <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">"Congenital nephrotic syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The administration of albumin to raise the plasma oncotic pressure can increase sodium excretion and lead to resolution of edema [<a href="#rid16">16,17</a>]. However, this response is not seen in all patients and is not predictably seen in the same patient studied on several occasions [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Evidence supporting primary renal sodium retention</span><span class="headingEndMark"> — </span>Studies in experimental animals with unilateral nephrotic syndrome or glomerulonephritis suggest that primary sodium retention in these disorders is due to increased sodium reabsorption in the collecting tubules (<a class="graphic graphic_figure graphicRef82649" href="/z/d/graphic/82649.html" rel="external">figure 2</a>) [<a href="#rid18">18,19</a>], which is also the site of action of atrial natriuretic peptide (ANP) and the related kidney hormone urodilatin. This has been called the overfill hypothesis since primary renal sodium retention leads to volume expansion, as opposed to underfilling, as discussed in the preceding section.</p><p>Several different abnormalities in tubular function have been identified in the nephrotic syndrome, which could increase sodium reabsorption:</p><p class="bulletIndent1"><span class="glyph">●</span>There is increased activity of the Na-K-ATPase pump in the cortical collecting tubule but not other nephron segments [<a href="#rid20">20</a>]. This pump provides the energy for active sodium transport by pumping reabsorbed sodium out of the cell into the peritubular capillary. However, it is not clear if this represents a primary effect or is simply a secondary marker for increased sodium transport at this site.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both experimental and human studies have documented relative resistance to atrial natriuretic peptide and urodilatin in the nephrotic syndrome [<a href="#rid1">1,21-23</a>]. This defect is due at least in part to increased phosphodiesterase activity in the collecting tubules, leading to more rapid degradation of the second messenger of ANP, cyclic GMP (guanosine monophosphate). Infusion of a phosphodiesterase inhibitor largely reverses this defect and restores the normal natriuretic response to volume expansion [<a href="#rid21">21,22</a>]. The mechanism by which phosphodiesterase activity is increased in the nephrotic syndrome is not known but phosphodiesterase-mediated resistance to ANP has also been described in heart failure and cirrhosis [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased activity of the epithelial sodium channel (ENaC) may contribute to sodium retention [<a href="#rid24">24,25</a>]. Serine proteases are aberrantly filtered in the nephrotic syndrome, leading to increased concentration in the urine. Plasminogen (which is activated by epithelial urokinase-type plasminogen activator [uPA] to plasmin) in nephrotic urine may activate ENaC via proteolytic cleavage of the gamma chain, providing a potential mechanism by which filtered proteins cause sodium retention. It also explains the observation that remission from the nephrotic syndrome is generally preceded by a decrease in urinary protein excretion. In an animal model of nephrotic syndrome, mice treated with the serine protease inhibitor aprotinin normalized urinary serine protease activity and prevented sodium retention [<a href="#rid26">26</a>]. Other proteases, including cathepsin-B, have also been reported to increase ENaC activity in experimental nephrotic syndrome [<a href="#rid27">27</a>]. When rats with nephrosis were treated with the ENaC inhibitor <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>, sodium retention was mitigated [<a href="#rid28">28</a>]. Case reports of the efficacy of ENaC inhibitors in patients with resistant nephrotic edema have also been described [<a href="#rid29">29,30</a>].</p><p></p><p>Another possible contributor to renal sodium retention is enhanced proximal tubular reabsorption via increased activity of the sodium-hydrogen exchanger (NHE3) that mediates a large part of proximal sodium reabsorption [<a href="#rid31">31,32</a>]. However, even if proximal sodium reabsorption were increased, it might not contribute to sodium retention, since, as mentioned above in the unilateral nephrotic syndrome model, delivery to the end-distal tubule appears to be the same in nephrotic and non-nephrotic kidneys (<a class="graphic graphic_figure graphicRef82649" href="/z/d/graphic/82649.html" rel="external">figure 2</a>) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H613074727"><span class="h3">Volume regulatory hormones</span><span class="headingEndMark"> — </span>The plasma levels of volume regulatory hormones have been measured in nephrotic patients to more clearly define the volume status [<a href="#rid33">33</a>]. Normal subjects ingesting and excreting 20 mEq of sodium per day have a high plasma renin activity (PRA) and low atrial natriuretic peptide (ANP) levels. In comparison, most nephrotic patients (at the same low level of sodium excretion) have renin and ANP levels that are equivalent to those in normal subjects ingesting 120 to 150 mEq/day (<a class="graphic graphic_figure graphicRef50596" href="/z/d/graphic/50596.html" rel="external">figure 3</a>).</p><p>These findings suggest at least a component of primary renal sodium retention since sodium excretion is much lower than expected from the plasma hormone levels. However, nephrotic patients with edema do not have the hormonal profile (very low PRA, very high ANP) seen in acute glomerulonephritis, which is thought to represent an example of pure volume expansion due to renal sodium retention (<a class="graphic graphic_figure graphicRef50596" href="/z/d/graphic/50596.html" rel="external">figure 3</a>) [<a href="#rid33">33</a>].</p><p>Another finding that might favor of a component of underfilling in the nephrotic syndrome is the frequent presence of nonosmotic release of antidiuretic hormone [<a href="#rid34">34,35</a>]. However, this change is not of major physiologic importance since, in the absence of kidney failure, nephrotic patients do not usually develop the water retention and hyponatremia seen in patients with heart failure and cirrhosis, conditions in which decreased effective circulating volume provides the stimulus for hormonal activation. (See  <a class="medical medical_review" href="/z/d/html/2321.html" rel="external">"Hyponatremia in patients with heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Response to glucocorticoids in minimal change disease</span><span class="headingEndMark"> — </span>Observations in patients with minimal change disease have suggested a relatively minor role for hypoalbuminemia (unless severe) in the development of nephrotic edema in many patients. When remission is induced by glucocorticoids, the peak diuresis typically occurs <strong>before</strong> there is a substantial rise in the plasma oncotic pressure (<a class="graphic graphic_figure graphicRef55827" href="/z/d/graphic/55827.html" rel="external">figure 4</a>) [<a href="#rid36">36</a>]. It is possible, however, that even a small elevation in the plasma albumin concentration is sufficient to reverse underfilling and permit a diuresis. Thus, these observations do not necessarily exclude a pathogenetic role for underfilling.</p><p class="headingAnchor" id="H8"><span class="h2">Varying mechanisms in childhood minimal change disease</span><span class="headingEndMark"> — </span>A study in children with minimal change disease sheds some light on the often conflicting findings noted above since it suggests that patients with the same disease may have different mechanisms of edema [<a href="#rid12">12</a>]. Thirty children with minimal change disease in remission were monitored carefully and studied within a <strong>few days</strong> of the onset of relapse as indicated by persistent 3+ findings on the urine dipstick for protein. When first evaluated, three different groups were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Nine children appeared to have <strong>primary renal sodium retention</strong>. They were relatively normoalbuminemic (mean plasma albumin concentration 3.7 g/dL [37 g/L]), had a reduced fractional excretion of sodium (0.5 versus 1.1 percent in remission), and signs of modest volume expansion (weight gain, increased blood volume) but no overt edema since the degree of volume expansion was not yet great enough.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thirteen children appeared to have <strong>underfilling</strong>. In addition to edema, overt nephrotic syndrome, and a mean plasma albumin concentration of 1.6 g/dL (16 g/L), they also had one or more symptoms suggestive of volume depletion (tachycardia, peripheral vasoconstriction, oliguria), marked elevations in the plasma renin activity and plasma concentrations of aldosterone and norepinephrine, low plasma concentration of atrial natriuretic peptide, and a low glomerular filtration rate. In one child, the symptoms and neurohumoral activation were transiently improved by albumin infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eight children had edema, overt nephrotic syndrome, and a mean plasma albumin concentration of 1.8 g/dL (18 g/L), but no signs of hypovolemia.</p><p></p><p>The factors responsible for the differences between the last two groups with the same degree of hypoalbuminemia are not well understood. One possibility is that patients with rapid protein loss may have a reduction in the transcapillary oncotic pressure gradient because there has not been sufficient time for the interstitial oncotic pressure to fall. If this were the case, then underfilling should be transient, disappearing as the interstitial oncotic pressure fell in parallel to the change in the plasma oncotic pressure.</p><p class="headingAnchor" id="H10"><span class="h2">Hypoalbuminemia in other edematous disorders</span><span class="headingEndMark"> — </span>Observations in conditions other than the nephrotic syndrome have been used to evaluate the role of hypoalbuminemia and presumed underfilling in the pathogenesis of edema. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with cirrhosis are frequently hypoalbuminemic but typically present with ascites (due to postsinusoidal obstruction), not prominent peripheral edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Edema is common in the malnutrition syndrome kwashiorkor. Although this complication has been ascribed to hypoalbuminemia, it has been suggested that increased generation of cysteinyl leukotrienes may be of major importance by increasing capillary permeability [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Conclusion</span><span class="headingEndMark"> — </span>It seems likely that the relative importance of underfilling due to hypoalbuminemia and overfilling due to primary renal sodium retention varies among patients and, perhaps at different times, in the same patient [<a href="#rid12">12</a>]. Some have suggested that the kidney findings at presentation may be helpful but the predictive value is uncertain [<a href="#rid11">11,38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with elevated intravascular volume due to primary renal sodium retention are more likely have a glomerular filtration rate less than 50 percent of normal, a plasma albumin concentration greater than 2 g/dL (20 g/L), and hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with underfilling are more likely to have a glomerular filtration rate greater than 75 percent of normal and either minimal change disease of acute onset or severe hypoalbuminemia (often below 1 g/dL [10 g/L]) [<a href="#rid12">12,15</a>].</p><p></p><p>Independent of the mechanism of nephrotic edema, underfilling can occur after the initiation of diuretic therapy as discussed below. (See <a class="local">'Diuretics and sodium restriction'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The above discussion on the roles of underfilling and primary renal sodium retention was provided to describe the mechanisms of edema formation in the nephrotic syndrome. However, distinction between these mechanisms prior to the initiation of diuretic therapy (eg, measurement of plasma renin activity, plasma aldosterone, and plasma natriuretic peptides) is <strong>not</strong> made in routine clinical practice. Clinically, children may present with underfilling or primary sodium retention, whereas primary sodium retention predominates in adults. (See  <a class="medical medical_review" href="/z/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Diuretics'</a>.)</p><p class="headingAnchor" id="H23421802"><span class="h2">Diuretics and sodium restriction</span><span class="headingEndMark"> — </span>All patients with nephrotic edema are initially treated with diuretic therapy and dietary sodium restriction (approximately 2 g/day) and monitored for clinical signs of hypovolemia [<a href="#rid39">39</a>]. The excess fluid can usually be removed, at least initially, without inducing clinically significant plasma volume depletion as defined by an otherwise unexplained elevation in serum creatinine or clinical manifestations of hypovolemia (eg, weakness, orthostatic hypotension, and/or cool extremities) [<a href="#rid7">7</a>]. Careful monitoring is required and diuretic therapy should be at least temporarily discontinued if these manifestations occur. (See  <a class="medical medical_review" href="/z/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">"Loop diuretics: Dosing and major side effects", section on 'Major side effects'</a>.)</p><p>Most patients respond well to loop diuretics, although there is generally a lesser natriuresis than seen in normal subjects even when the glomerular filtration rate is normal or near normal [<a href="#rid40">40-42</a>]. Several factors are thought to play an important role in this relative diuretic resistance:</p><p class="bulletIndent1"><span class="glyph">●</span>All the commonly used diuretics are highly protein-bound. This limits the diuretic to the vascular space, thereby maximizing its rate of delivery to the kidney. The degree of protein-binding is reduced with hypoalbuminemia, resulting in a larger extravascular space of distribution and a slower rate of delivery to the kidney [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some of the diuretic that enters the tubular lumen is bound to filtered albumin and rendered inactive [<a href="#rid43">43,44</a>]. In experimental in vivo microperfusion of the loop of Henle, the addition of albumin to the perfusate in a concentration similar to that seen in the tubular lumen in the nephrotic syndrome diminishes the response to intraluminal <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> by approximately 50 percent [<a href="#rid43">43</a>]. However, it is uncertain if this mechanism is important in humans. In one study of seven patients with nephrotic syndrome, blocking of albumin binding to furosemide by the administration of sulfisoxazole had no effect on the diuretic response [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies in rats with drug-induced nephrotic syndrome suggest that the loop of Henle may be relatively resistant to loop diuretics [<a href="#rid46">46</a>].</p><p></p><p>The net effect is that the effective diuretic dose is usually higher in patients with nephrotic syndrome compared with other edematous disorders. As an example, the maximum dose of intravenous <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> is 40 to 80 mg in edematous patients with heart failure or cirrhosis who have a relatively normal glomerular filtration rate, but may be as high as 80 to 120 mg in patients with the nephrotic syndrome and a relatively normal glomerular filtration rate [<a href="#rid12">12</a>]. Patients who do not respond adequately may require the addition of a thiazide diuretic to block sodium reabsorption at several sites in the nephron. Alternatively, ENaC inhibitors such as <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a> and <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> may be utilized in refractory patients [<a href="#rid29">29,30,47,48</a>]. <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">Acetazolamide</a> [<a href="#rid49">49</a>] has been similarly used with loop diuretics in patients with refractory edema. The issue of refractory edema is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">"Loop diuretics: Dosing and major side effects"</a> and  <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">"Causes and treatment of refractory edema in adults"</a>.)</p><p>It has been suggested that the diuresis can be enhanced in patients with marked hypoalbuminemia by infusing a solution in which a loop diuretic has been added to salt-poor albumin, creating loop diuretic-albumin complexes that keep the diuretic within the vascular space, thereby increasing the rate of loop diuretic secretion into the tubular lumen. However, the addition of albumin to <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> in this manner has not been shown to improve diuresis [<a href="#rid50">50</a>]. Administering albumin and diuretics separately leads to only a modest increase in mean daily urine volume and sodium excretion in adults [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">"Causes and treatment of refractory edema in adults"</a>.)</p><p>In children, the addition of albumin appears to produce a more profound diuresis, at least in a subpopulation of patients [<a href="#rid52">52</a>], particularly those with a reduced effective arterial blood volume. In one study, for example, 20 children with nephrotic syndrome were treated with diuretics or, if the fractional excretion of sodium (FENa) was less than 0.2 percent (used to identify a reduced effective arterial blood volume), diuretics plus albumin infusion [<a href="#rid53">53</a>]. With diuretics plus albumin infusion, patients with a FENa less than 0.2 percent achieved a similar diuresis as diuretic therapy in patients who had a higher FENa.</p><p class="headingAnchor" id="H704527486"><span class="h2">Angiotensin inhibition</span><span class="headingEndMark"> — </span>Almost all patients with proteinuric chronic kidney disease are given, in addition to appropriate therapy for the underlying disease, an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) in an attempt to slow the progressive loss of kidney function. A possible additional benefit of such therapy among diuretic-resistant patients is a lesser degree of albuminuria, which might increase the plasma albumin concentration and enhance the response to diuretics [<a href="#rid42">42</a>]. Minimal change disease is a major exception to this approach since remission can usually be induced with glucocorticoid therapy. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults", section on 'Choice of initial therapy'</a>.)</p><p class="headingAnchor" id="H13323204"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4413.html" rel="external">"Patient education: Edema (swelling) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4423.html" rel="external">"Patient education: The nephrotic syndrome (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1038562"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Edema (swelling) is the major clinical manifestation of the nephrotic syndrome. There are two mechanisms responsible for the development of edema in patients with the nephrotic syndrome: low plasma levels of albumin which promotes the movement of fluid out of the vascular, leading to underfilling of the vasculature and secondary sodium retention; and primary sodium retention induced by the kidney disease. It is likely that both can contribute to a variable degree in individual patients. (See <a class="local">'Underfilling versus renal sodium retention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Underfilling </strong>– Although an important role of arterial underfilling appears to be predicted from Starling's law, the gradual fall in plasma oncotic pressure in the nephrotic syndrome is associated with a parallel decline in interstitial oncotic pressure, which minimizes the change in the transcapillary oncotic pressure gradient. This minimizes fluid movement out of the vascular space, resulting in many patients in relative maintenance of the plasma volume. (See <a class="local">'Starling's law'</a> above.)</p><p></p><p class="bulletIndent2">However, underfilling does occur, particularly in children with minimal change disease of acute onset or severe hypoalbuminemia (often below 1 g/dL [10 g/L]). Such patients may have symptoms or signs of hypovolemia, including tachycardia, peripheral vasoconstriction (eg, cold hands and feet), and oliguria. In the absence of symptoms or signs, the major manifestation of underfilling is an otherwise unexplained elevation in serum creatinine with diuretic therapy in patients who still have edema. (See <a class="local">'Evidence supporting underfilling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary renal sodium retention </strong>– The presence of primary renal sodium retention as a cause for nephrotic edema is supported by both experimental models and observations in nephrotic patients. Experimental models suggest that the sodium retention is due to increased sodium reabsorption in the collecting tubules. (See <a class="local">'Evidence supporting primary renal sodium retention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diuretics and sodium restriction </strong>– We recommend that patients with nephrotic edema who do not have otherwise unexplained signs of symptoms of hypovolemia (eg, tachycardia, peripheral vasoconstriction, cold hands and feet) be treated with diuretic therapy and dietary sodium restriction (approximately 2 g of sodium per day) (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Excess fluid can usually be removed without inducing clinically significant plasma volume depletion. The effective diuretic dose is usually higher in patients with nephrotic syndrome compared with other edematous disorders and the addition of a thiazide diuretic or, alternatively, <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a> or <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a>, may be required in patients with refractory edema. In nephrotic children with clinical signs of reduced effective arterial blood volume or a low fractional excretion of sodium (ie, less than 0.2 percent), the addition of albumin may be considered. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Angiotensin inhibition </strong>– Almost all patients with proteinuric chronic kidney disease are given, in addition to therapy specific for the underlying cause of the nephrotic syndrome, an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) in an attempt to slow the progressive loss of kidney function. Minimal change disease is a major exception to this approach since remission can usually be induced with glucocorticoid therapy. A possible additional benefit of angiotensin inhibition in diuretic-resistant patients is a decrease in the severity of albuminuria, which might increase the plasma albumin concentration and enhance the response to diuretics. (See <a class="local">'Angiotensin inhibition'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Perico N, Remuzzi G. Edema of the nephrotic syndrome: the role of the atrial peptide system. Am J Kidney Dis 1993; 22:355.</a></li><li><a class="nounderline abstract_t">Humphreys MH. Mechanisms and management of nephrotic edema. Kidney Int 1994; 45:266.</a></li><li><a class="nounderline abstract_t">Noddeland H, Riisnes SM, Fadnes HO. Interstitial fluid colloid osmotic and hydrostatic pressures in subcutaneous tissue of patients with nephrotic syndrome. Scand J Clin Lab Invest 1982; 42:139.</a></li><li><a class="nounderline abstract_t">Koomans HA, Kortlandt W, Geers AB, Dorhout Mees EJ. Lowered protein content of tissue fluid in patients with the nephrotic syndrome: observations during disease and recovery. Nephron 1985; 40:391.</a></li><li><a class="nounderline abstract_t">Aukland K, Nicolaysen G. Interstitial fluid volume: local regulatory mechanisms. Physiol Rev 1981; 61:556.</a></li><li><a class="nounderline abstract_t">Geers AB, Koomans HA, Roos JC, et al. Functional relationships in the nephrotic syndrome. Kidney Int 1984; 26:324.</a></li><li><a class="nounderline abstract_t">Geers AB, Koomans HA, Roos JC, Dorhout Mees EJ. Preservation of blood volume during edema removal in nephrotic subjects. Kidney Int 1985; 28:652.</a></li><li><a class="nounderline abstract_t">Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.</a></li><li><a class="nounderline abstract_t">Watkins L Jr, Burton JA, Haber E, et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976; 57:1606.</a></li><li><a class="nounderline abstract_t">EISENBERG S. Blood volume in patients with acute glomerulonephritis as determined by radioactive chromium tagged red cells. Am J Med 1959; 27:241.</a></li><li><a class="nounderline abstract_t">Meltzer JI, Keim HJ, Laragh JH, et al. Nephrotic syndrome: vasoconstriction and hypervolemic types indicated by renin-sodium profiling. Ann Intern Med 1979; 91:688.</a></li><li><a class="nounderline abstract_t">Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.</a></li><li><a class="nounderline abstract_t">Manning RD Jr, Guyton AC. Effects of hypoproteinemia on fluid volumes and arterial pressure. Am J Physiol 1983; 245:H284.</a></li><li><a class="nounderline abstract_t">Manning RD Jr. Effects of hypoproteinemia on renal hemodynamics, arterial pressure, and fluid volume. Am J Physiol 1987; 252:F91.</a></li><li><a class="nounderline abstract_t">Vande Walle JG, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J Am Soc Nephrol 1999; 10:323.</a></li><li><a class="nounderline abstract_t">EDER HA, LAUSON HD, CHINARD FP, et al. A study of the mechanisms of edema formation in patients with the nephrotic syndrome. J Clin Invest 1954; 33:636.</a></li><li><a class="nounderline abstract_t">LUETSCHER JA Jr, HALL AD, KREMER VL. Treatment of nephrosis with concentrated human serum albumin. II. Effects on renal function and on excretion of water and some electrolytes. J Clin Invest 1950; 29:896.</a></li><li><a class="nounderline abstract_t">Ichikawa I, Rennke HG, Hoyer JR, et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983; 71:91.</a></li><li><a class="nounderline abstract_t">Buerkert J, Martin DR, Trigg D, Simon EE. Sodium handling by deep nephrons and the terminal collecting duct in glomerulonephritis. Kidney Int 1991; 39:850.</a></li><li><a class="nounderline abstract_t">Féraille E, Vogt B, Rousselot M, et al. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest 1993; 91:1295.</a></li><li><a class="nounderline abstract_t">Valentin JP, Ying WZ, Sechi LA, et al. Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis. J Am Soc Nephrol 1996; 7:582.</a></li><li><a class="nounderline abstract_t">Valentin JP, Qiu C, Muldowney WP, et al. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992; 90:1302.</a></li><li><a class="nounderline abstract_t">Lee EY, Humphreys MH. Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol 1996; 271:F3.</a></li><li><a class="nounderline abstract_t">Svenningsen P, Bistrup C, Friis UG, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20:299.</a></li><li><a class="nounderline abstract_t">Passero CJ, Mueller GM, Rondon-Berrios H, et al. Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. J Biol Chem 2008; 283:36586.</a></li><li><a class="nounderline abstract_t">Bohnert BN, Menacher M, Janessa A, et al. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int 2018; 93:159.</a></li><li><a class="nounderline abstract_t">Larionov A, Dahlke E, Kunke M, et al. Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome. J Cell Mol Med 2019; 23:6543.</a></li><li><a class="nounderline abstract_t">Stæhr M, Buhl KB, Andersen RF, et al. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. Am J Physiol Renal Physiol 2015; 309:F235.</a></li><li><a class="nounderline abstract_t">Yamaguchi E, Yoshikawa K, Nakaya I, et al. Liddle's-like syndrome associated with nephrotic syndrome secondary to membranous nephropathy: the first case report. BMC Nephrol 2018; 19:122.</a></li><li><a class="nounderline abstract_t">Hinrichs GR, Mortensen LA, Jensen BL, Bistrup C. Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report. Physiol Rep 2018; 6:e13743.</a></li><li><a class="nounderline abstract_t">Besse-Eschmann V, Klisic J, Nief V, et al. Regulation of the proximal tubular sodium/proton exchanger NHE3 in rats with puromycin aminonucleoside (PAN)-induced nephrotic syndrome. J Am Soc Nephrol 2002; 13:2199.</a></li><li><a class="nounderline abstract_t">Klisic J, Zhang J, Nief V, et al. Albumin regulates the Na+/H+ exchanger 3 in OKP cells. J Am Soc Nephrol 2003; 14:3008.</a></li><li><a class="nounderline abstract_t">Rodríguez-Iturbe B, Colic D, Parra G, Gutkowska J. Atrial natriuretic factor in the acute nephritic and nephrotic syndromes. Kidney Int 1990; 38:512.</a></li><li><a class="nounderline abstract_t">Usberti M, Federico S, Meccariello S, et al. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int 1984; 25:422.</a></li><li><a class="nounderline abstract_t">Pyo HJ, Summer SN, Niederberger M, et al. Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome. Am J Kidney Dis 1995; 25:58.</a></li><li><a class="nounderline abstract_t">Koomans HA, Boer WH, Dorhout Mees EJ. Renal function during recovery from minimal lesions nephrotic syndrome. Nephron 1987; 47:173.</a></li><li><a class="nounderline abstract_t">Mayatepek E, Becker K, Gana L, et al. Leukotrienes in the pathophysiology of kwashiorkor. Lancet 1993; 342:958.</a></li><li><a class="nounderline abstract_t">Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998; 53:1111.</a></li><li><a class="nounderline abstract_t">Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004; 62:245.</a></li><li><a class="nounderline abstract_t">Smith DE, Hyneck ML, Berardi RR, Port FK. Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients. J Pharm Sci 1985; 74:603.</a></li><li><a class="nounderline abstract_t">Keller E, Hoppe-Seyler G, Schollmeyer P. Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin Pharmacol Ther 1982; 32:442.</a></li><li><a class="nounderline abstract_t">Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002; 13:798.</a></li><li><a class="nounderline abstract_t">Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990; 252:1097.</a></li><li><a class="nounderline abstract_t">Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 1991; 40:418.</a></li><li><a class="nounderline abstract_t">Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 2000; 11:1100.</a></li><li><a class="nounderline abstract_t">Kirchner KA, Voelker JR, Brater DC. Tubular resistance to furosemide contributes to the attenuated diuretic response in nephrotic rats. J Am Soc Nephrol 1992; 2:1201.</a></li><li><a class="nounderline abstract_t">Deschênes G, Guigonis V, Doucet A. [Molecular mechanism of edema formation in nephrotic syndrome]. Arch Pediatr 2004; 11:1084.</a></li><li><a class="nounderline abstract_t">Hoorn EJ, Ellison DH. Diuretic Resistance. Am J Kidney Dis 2017; 69:136.</a></li><li><a class="nounderline abstract_t">Fallahzadeh MA, Dormanesh B, Fallahzadeh MK, et al. Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Furosemide and Hydrochlorothiazide Followed by Furosemide for the Treatment of Adults With Nephrotic Edema: A Randomized Trial. Am J Kidney Dis 2017; 69:420.</a></li><li><a class="nounderline abstract_t">Chalasani N, Gorski JC, Horlander JC Sr, et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 2001; 12:1010.</a></li><li><a class="nounderline abstract_t">Fliser D, Zurbrüggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999; 55:629.</a></li><li><a class="nounderline abstract_t">Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol 2009; 24:775.</a></li><li><a class="nounderline abstract_t">Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study. Clin J Am Soc Nephrol 2009; 4:907.</a></li></ol></div><div id="topicVersionRevision">Topic 3044 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372830" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Edema of the nephrotic syndrome: the role of the atrial peptide system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127018" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mechanisms and management of nephrotic edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7134798" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interstitial fluid colloid osmotic and hydrostatic pressures in subcutaneous tissue of patients with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4022206" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lowered protein content of tissue fluid in patients with the nephrotic syndrome: observations during disease and recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7019943" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Interstitial fluid volume: local regulatory mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6392692" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Functional relationships in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4087686" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preservation of blood volume during edema removal in nephrotic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7006851" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/180056" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The renin-angiotensin-aldosterone system in congestive failure in conscious dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13819755" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Blood volume in patients with acute glomerulonephritis as determined by radioactive chromium tagged red cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/496101" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nephrotic syndrome: vasoconstriction and hypervolemic types indicated by renin-sodium profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603230" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6881362" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of hypoproteinemia on fluid volumes and arterial pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3544869" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of hypoproteinemia on renal hemodynamics, arterial pressure, and fluid volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215332" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13152204" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A study of the mechanisms of edema formation in patients with the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15436857" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of nephrosis with concentrated human serum albumin. II. Effects on renal function and on excretion of water and some electrolytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848563" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067201" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sodium handling by deep nephrons and the terminal collecting duct in glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386183" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8724892" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1328296" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8760236" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073825" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Plasmin in nephrotic urine activates the epithelial sodium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981180" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Plasmin activates epithelial Na+ channels by cleaving the gamma subunit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042083" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31368174" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972510" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792170" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Liddle's-like syndrome associated with nephrotic syndrome secondary to membranous nephropathy: the first case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29939487" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191963" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Regulation of the proximal tubular sodium/proton exchanger NHE3 in rats with puromycin aminonucleoside (PAN)-induced nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638900" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Albumin regulates the Na+/H+ exchanger 3 in OKP cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2146429" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Atrial natriuretic factor in the acute nephritic and nephrotic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727137" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7810534" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3317090" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Renal function during recovery from minimal lesions nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105215" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Leukotrienes in the pathophysiology of kwashiorkor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573524" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15524054" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Complications of the nephrotic syndrome and their treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4020645" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7116760" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Disposition and diuretic effect of furosemide in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856788" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New insights into diuretic use in patients with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2319462" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1724020" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Binding inhibitors restore furosemide potency in tubule fluid containing albumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10820174" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591361" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tubular resistance to furosemide contributes to the attenuated diuretic response in nephrotic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15351000" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : [Molecular mechanism of edema formation in nephrotic syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27814935" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diuretic Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28043731" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Furosemide and Hydrochlorothiazide Followed by Furosemide for the Treatment of Adults With Nephrotic Edema: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316860" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987087" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Coadministration of albumin and furosemide in patients with the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142668" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406963" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
